The efficacy and safety of DW1601 in patients with acute bronchitis: a multi-center, randomized, double-blind, phase III clinical trial
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: DW1601, an oral fixed dose combination syrup composed of DW16011 and Pelargonium sidoides, was developed to enhance the symptom relief effect in patients with acute bronchitis. We evaluated the efficacy and safety of DW1601 compared to DW16011 or P. sidoides for treatment of acute bronchitis using a randomized, double-blind, placebocontrolled, multi-centre trial design. Methods: A total of 204 patients with acute bronchitis was randomized 1:1:1 to receive DW1601 (n = 67), DW16011 (n = 70), or P. sidoides (n = 64) for 7 days. The primary outcome was efficacy of DW1601 compared to DW16011 or P. sidoides in reducing the total bronchitis severity score (BSS) at day 4 of treatment. Secondary endpoints were changes in total and symptomspecific BSS, response rate and patient satisfaction rate. Safety analysis was assessed at day 7. Results: At 4 days after medication, decrease of total BSS from baseline was significantly greater in the DW1601 group than in the DW16011 group (–3.51 ± 0.18 vs. –2.65 ± 0.18, p = 0.001) or P. sidoides group (–3.56 ± 0.18 vs. –2.64 ± 0.19, p < 0.001). In addition, the BSS total score at day 7 and the BSS cough and sputum component scores at days 4 and 7 were significantly more improved with DW1601 treatment compared with the DW16011 group or P. sidoides group. Participants treated with DW1601 showed higher rates of response and satisfaction than control groups (response rate, DW1601, 100% vs. DW16011, 85.7% vs. P. sidoides, 85.9%; satisfaction rate, DW1601, 92.6% vs. DW16011, 82.9% vs. P. sidoides, 81.2%). Significant adverse events were not observed in the DW1601 group. Conclusions: DW1601 is superior to DW16011 or P. sidoides in improving symptoms of acute bronchitis.
Abstract
Background/Aims: DW1601, an oral fixed dose combination syrup composed of DW16011 and Pelargonium sidoides, was developed to enhance the symptom relief effect in patients with acute bronchitis. We evaluated the efficacy and safety of DW1601 compared to DW16011 or P. sidoides for treatment of acute bronchitis using a randomized, double-blind, placebocontrolled, multi-centre trial design. Methods: A total of 204 patients with acute bronchitis was randomized 1:1:1 to receive DW1601 (n = 67), DW16011 (n = 70), or P. sidoides (n = 64) for 7 days. The primary outcome was efficacy of DW1601 compared to DW16011 or P. sidoides in reducing the total bronchitis severity score (BSS) at day 4 of treatment. Secondary endpoints were changes in total and symptomspecific BSS, response rate and patient satisfaction rate. Safety analysis was assessed at day 7. Results: At 4 days after medication, decrease of total BSS from baseline was significantly greater in the DW1601 group than in the DW16011 group (–3.51 ± 0.18 vs. –2.65 ± 0.18, p = 0.001) or P. sidoides group (–3.56 ± 0.18 vs. –2.64 ± 0.19, p < 0.001). In addition, the BSS total score at day 7 and the BSS cough and sputum component scores at days 4 and 7 were significantly more improved with DW1601 treatment compared with the DW16011 group or P. sidoides group. Participants treated with DW1601 showed higher rates of response and satisfaction than control groups (response rate, DW1601, 100% vs. DW16011, 85.7% vs. P. sidoides, 85.9%; satisfaction rate, DW1601, 92.6% vs. DW16011, 82.9% vs. P. sidoides, 81.2%). Significant adverse events were not observed in the DW1601 group. Conclusions: DW1601 is superior to DW16011 or P. sidoides in improving symptoms of acute bronchitis.
참고문헌 (28)
- Smith MP, "Acute cough due to acute bronchitis in immunocompetent adult outpatients : CHEST expert panel report", Chest, 157, pp.1256~1265 (2020)
- Kinkade S, "Acute bronchitis", Am Fam Physician, 94, pp.560~565 (2016)
- Gonzales R, "Uncomplicated acute bronchitis", Ann Intern Med, 133, pp.981~991 (2000)
- Wenzel RP, "Clinical practice. Acute bronchitis", N Engl J Med, 355, pp.2125~2130 (2006)
- Malesker MA, "Pharmacologic and nonpharmacologic treatment for acute cough associated with the common cold:CHEST expert panel report", Chest, 152, pp.1021~1037 (2017)
- Keller JA, "Translating cough mechanisms into better cough suppressants", Chest, 152, pp.833~841 (2017)
- Young EC, "Quality of life in patients with chronic cough", Ther Adv Respir Dis, 4, pp.49~55 (2010)
- Bagcchi S, "Stigma during the COVID-19 pandemic", Lancet Infect Dis, 20, pp.782~ (2020)
- Brooks SK, "The psychological impact of quarantine and how to reduce it : rapid review of the evidence", Lancet, 395, pp.912~920 (2020)
- Smith SM, "Antibiotics for acute bronchitis", Cochrane Database Syst Rev, 6, pp.CD000245~ (2017)
- Albert RH, "Diagnosis and treatment of acute bronchitis", Am Fam Physician, 82, pp.1345~1350 (2010)
- Smith SM, "Antibiotics for acute bronchitis", JAMA, 312, pp.2678~2679 (2014)
- Hill AT, "Adult outpatients with acute cough due to suspected pneumonia or influenza : CHEST guideline and expert panel report", Chest, 155, pp.155~167 (2019)
- Agbabiaka TB, "Pelargonium sidoides for acute bronchitis : a systematic review and meta-analysis", Phytomedicine, 15, pp.378~385 (2008)
- Timmer A, "Pelargonium sidoides extract for treating acute respiratory tract infections", Cochrane Database Syst Rev, 10, pp.CD006323~ (2013)
- Matthys H, "Pelargonium sidoides preparation (EPs 7630) in the treatment of acute bronchitis in adults and children", Phytomedicine, 14(Suppl 6), pp.69~73 (2007)
- Bao Y, "Evaluation of pharmacodynamic activities of EPs® 7630, a special extract from roots of Pelargonium sidoides, in animals models of cough, secretolytic activity and acute bronchitis", Phytomedicine, 22, pp.504~509 (2015)
- Kamin W, "Efficacy and tolerability of Eps 7630 in children and adolescents with acute bronchitis : a randomized, double-blind, placebo-controlled multicenter trial with a herbal drug preparation from Pelargonium sidoides roots", Int J Clin Pharmacol Ther, 48, pp.184~191 (2010)
- Riley DS, "Treatment with EPs 7630, a Pelargonium sidoides root extract, is effective and safe in patients with the common cold:results from a randomized, double blind, placebo-controlled clinical trial", Integr Med (Encinitas), 18, pp.42~51 (2019)
- Matthys H, "Positioning of the Bronchitis Severity Score(BSS)for standardised use in clinical studies", Curr Med Res Opin, 29, pp.1383~1390 (2013)
- Kardos P, "Assessment of the effect of pharmacotherapy in common cold", acute bronchitis : the Bronchitis Severity Scale(BSS), 2014, pp.68, 542~546
- Visca D, "Management of chronic refractory cough in adults", Eur J Intern Med, 81, pp.15~21 (2020)
- Morice AH, "ERS guidelines on the diagnosis and treatment of chronic cough in adults and children", Eur Respir J, 55, pp.1901136~ (2020)
- Silveira D, "COVID-19 : is there evidence for the use of herbal medicines as adjuvant symptomatic therapy?", Front Pharmacol, 11, pp.581840~ (2020)
- Papies J, "Antiviral and immunomodulatory effects of Pelargonium sidoides DC. Root extract EPs® 7630 in SARS-CoV-2-infected human lung cells", Front Pharmacol, 12, pp.757666~ (2021)
- Keck T, "Pelargonium extract EPs 7630 in the treatment of human corona virus-associated acute respiratory tract infections : a secondary subgroup-analysis of an open-label, uncontrolled clinical trial", Front Pharmacol, 12, pp.666546~ (2021)
- Beard JR, "The World report on ageing and health : a policy framework for healthy ageing", Lancet, 387, pp.2145~2154 (2016)
- Beard JR, "The world report on ageing and health", Gerontologist, 56(Suppl 2), pp.S163~S166 (2016)